Mucosal melanoma (MM) is a rare and aggressive type of melanoma that originates from the melanocytes in the oral cavity, nasal cavity, pharynx, larynx, esophagus, gastrointestinal tract, genitourinary tract, and the anorectal region, as well as the mucosal membranes that line these body cavities. Protheragen provides full-range diagnostics and therapeutics development services for mucosal melanoma (MM).
Overview of Mucosal Melanoma (MM)
Mucosal melanoma (MM) develops from melanocytes located in mucosal tissues and is an especially aggressive subtype of melanoma. It occurs in non-sun-exposed areas like the gastrointestinal tract, nasal cavity, and other mucosal membranes. Unlike other melanoma cases, which constitute approximately 98% of the total, MM is diagnosed in late stages—mostly because of the asymptomatic and elusive nature of the melanoma's location. Unlike other forms of melanoma, the mucosal variant is genetically and molecularly distinct, and these differences, together with later-stage diagnosis, contribute to the relatively lower survival rate and therapeutic efficacy in these cases.
Fig.1 Main genes and their functional role in mucosal melanoma (MM). (Mao L.,
et al., 2021)
Diagnostics Development for Mucosal Melanoma (MM)
Genomic Sequencing
Genomic sequencing, including whole-genome and whole-exome sequencing, is a cornerstone in the diagnostics development for MM. These techniques enable the identification of specific genetic mutations and chromosomal aberrations that are characteristic of MM. For example, next-generation sequencing (NGS) has been instrumental in detecting actionable mutations in genes such as BRAF and KIT, which can guide personalized therapeutic strategies.
Immunohistochemistry (IHC)
IHC is a critical diagnostic tool used to detect specific protein markers such as S-100, HMB-45, Melan-A, and others, which support the diagnosis of melanoma. Additionally, IHC can be used to assess PD-L1 expression levels, which may predict response to immunotherapy. For instance, studies have shown that higher PD-L1 expression correlates with better response to immune checkpoint inhibitors in some cases.
Molecular Profiling
Molecular profiling involves the comprehensive analysis of genetic, epigenetic, and transcriptomic changes in MM. This approach helps in understanding the molecular landscape of the disease and identifying potential therapeutic targets. For example, the identification of mutations in the SF3B1 gene has led to the exploration of targeted therapies for this specific alteration.
Therapeutics Development for Mucosal Melanoma (MM)
- Immunotherapy
Immune checkpoint inhibitors targeting PD-1 (e.g., pembrolizumab, nivolumab) and CTLA-4 (e.g., ipilimumab) have shown some efficacy in MM, although response rates are generally lower than in cutaneous melanoma. Combination therapies, such as nivolumab plus ipilimumab, have demonstrated higher response rates but with increased toxicity. For example, a recent study reported an overall response rate (ORR) of 37.1% with the combination regimen compared to 23.3% and 8.3% for single-agent nivolumab and ipilimumab, respectively.
- Targeted Therapy
Targeted therapies focusing on specific genetic mutations are being explored. For instance, BRAF inhibitors (e.g., dabrafenib) and MEK inhibitors (e.g., trametinib) have shown promise in patients with BRAF-mutant MM. Additionally, KIT inhibitors (e.g., imatinib, nilotinib) have demonstrated clinical efficacy in patients with KIT-mutated MM. A phase II trial reported an ORR of 64% among patients with KIT mutations treated with imatinib.
- Combination Therapies
Combining immunotherapy with targeted therapies or anti-angiogenic agents (e.g., axitinib, bevacizumab) has shown synergistic effects in preclinical and early clinical studies. For example, a phase Ib trial combining axitinib with toripalimab reported an ORR of 48.3% and a disease control rate (DCR) of 86.2% in treatment-naïve patients with metastatic MM.
Table 1. Summary of immunotherapy clinical trials involving sub-analysis of patients with mucosal melanoma. (Santeufemia D. A., et al., 2023)
| Trial identifier |
Phase |
Number of patients |
Location |
Therapeutic |
Line of therapeutic |
Results |
| NCT02156804 |
II |
n = 1,008 (total)
n = 63 (MM) |
Europe |
Nivolumab |
2+ |
Median OS, 11.5 months (95% CI, 6.4–15.0 months) |
| NCT02821000 |
Ib |
n = 102 (total)
n = 15 (MM) |
China |
Pembrolizumab |
2 |
ORR, 13.3% (95% CI, 1.7%–40.5%) |
| NCT03013101 |
II |
n = 128 (total)
n = 22 (MM) |
China |
Toripalimab |
2 |
ORR, 0% (95% CI, 0.0%–17.6%) |
| NCT01844505 |
III |
n = 1,295 (total)
n = 79 (MM) |
International |
Nivolumab ± ipilimumab |
1 |
ORR, 43% with NIVO+IPI vs. 30% with NIVO and 7% with IPI |
| JapicCTI-142533 |
II |
n = 24 (total)
n = 6 (MM) |
Japan |
Nivolumab |
1 |
ORR, 33.3% (90% CI, 11.7%–65.3%) |
| JapicCTI-152869 |
II |
n = 30 (total)
n = 12 (MM) |
Japan |
Nivolumab ± ipilimumab |
1 |
ORR, 33.3% (95% CI, 9.9%–65.1%) |
| DeCOG-MM-PAL11-Trial |
II |
n = 103 (total)
n = 7 (MM) |
Germany |
Ipilimumab |
2+ |
Median OS, 9.6 months (95% CI, 1.6–11.1 months) |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen is dedicated to advancing the field of mucosal melanoma (MM) diagnostics and therapeutics. Our comprehensive services include genomic sequencing, immunohistochemistry, molecular profiling, and preclinical research. We specialize in developing customized therapeutic strategies, leveraging the latest advancements in immunotherapy and targeted therapy.
Disease Models
- Canine Oral Mucosal Melanoma Cell Line (COMM6605)
- Orthotopic Xenograft Models
- Subcutaneous Xenograft Models
- Genetically Engineered Mouse Models (GEMMs)
Protheragen's services offer a unique advantage in the field of MM diagnostics and therapeutics development. Our commitment to innovation and collaboration ensures that we stay at the forefront of scientific advancements, providing our clients with the best possible solutions for MM. If you are interested in our services, please feel free to contact us.
References
- Santeufemia, Davide Adriano, et al. "Current trends in mucosal melanomas: an overview." Cancers 15.5 (2023): 1356.
- Mao, Lili, et al. "Immunotherapy in acral and mucosal melanoma: current status and future directions." Frontiers in immunology 12 (2021): 680407.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
